Next Article in Journal
The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany
Next Article in Special Issue
The Role of ctDNA in Gastric Cancer
Previous Article in Journal
Can National Registries Contribute to Predict the Risk of Cancer? The Cancer Risk Assessment Model (CRAM)
Previous Article in Special Issue
Considerations and Challenges in the Management of the Older Patients with Gastric Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 15
10.3390/cancers14153824
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target

Cancers 2022, 14(15), 3824; https://doi.org/10.3390/cancers14153824
by Caroline Fong and Ian Chau *
Cancers 2022, 14(15), 3824; https://doi.org/10.3390/cancers14153824
Submission received: 24 June 2022 / Revised: 27 July 2022 / Accepted: 1 August 2022 / Published: 6 August 2022
(This article belongs to the Special Issue Contemporary Perspectives and Emerging Trends in the Management of Gastric Cancer)

Round 1

Reviewer 1 Report

This review article highlights different strategies to target HER2-related cancers, their mechanism of action, how resistance arises for the HER2 therapies and ways to overcome them.

I find the article highly useful in learning about gastric cancers. The tables describing the different lines of treatment, their clinical efficacy, patient responses and ongoing clinical trials are informative.

I would encourage the authors to make an illustration to explain the mechanism of action for the different therapies to increase the usefulness of the paper.

I recommend this paper for publication. Congratulations to the authors.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

 Excellent! I appreciate the great effort that the authors have made to write this review article.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 3 Report

The review of Fong and Chau is well written, and a contemporary update on recent developments for the tratemt of HER2-positive gastric cancers.

The authors may consider the following comments.

1) HER2 testing is notorously prone to sampling errors. When it comes to biopsies I advocate to refer to the recommendations set forth by hte American College of Pathologist, the Amercian Society of Clinical Pathology and ASCO (JCO 2017). A minimum of 5 tumor bearing biopsy specimens should be obtained for HER2-testing. Otherwise, HER2 status may reflect effect of sampling errors rather than treatment (Page 4).

2) The number of HER2-positive cases (according to ToGA criteria) eligible for treatment is still low. And despite recent advancements, the majority of gastric cancer patients will not benefit. This limitation merrits a notice in the conclusions.

3) However, having said this, ADCs bear the potential to increase patients eligible for HER2-targeted regimens (by including now also HER2 low cases). Therefore, the second sentence in the conlcusions may point out that the introduction of ADCs increases the numbers of patients eligible for targeted therapy, which I personally encounter one of the most important messages (apart form advancements made with ICIs).

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop